logo-loader
viewReNeuron Group PLC

Webcast of Preliminary Results

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .bc{size:595.3pt 841.9pt;margin:72.0pt 106.25pt 49.65pt 90.0pt;}div.bc{}h1.bz{text-indent:117.0pt}span.ca{font-weight:normal}table.cc{margin-left:-5.4pt;border-collapse:collapse}td.bx{width:176.65pt;padding:0cm 5.4pt 0cm 5.4pt}span.by{font-family:"Calibri","sans-serif"}td.bv{width:211.6pt;padding:0cm 5.4pt 0cm 5.4pt}h3.bw{text-align: right}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;} h1.bt{text-align: center}p.cd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.ce{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}span.bq{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cf{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;text-align:justify;text-justify:inter-ideograph}span.bo{font-family:"Calibri","sans-serif";color:black}p.cg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify; text-justify: inter-ideograph}table.ch{width:411.1pt}td.bk{width:67.26%;padding:0cm 0cm 0cm 0cm}p.ci{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold} span.bm{font-family:"Calibri","sans-serif"; color:black}td.bi{width:32.74%;padding:0cm 0cm 0cm 0cm}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: right}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-right: -104.85pt}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: right}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-bottom:13.5pt}span.ba{font-family:"Calibri","sans-serif";color:black;}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;text-justify:inter-ideograph;background:white} /**/
RNS Number : 5240C
ReNeuron Group plc
18 June 2019
 

 

 

18 June 2019

AIM: RENE

 

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Webcast of Preliminary Results

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will webcast the analyst briefing on the day of its preliminary results, Thursday 11 July 2019.

 

To listen to the webcast live, please log on to the following web address approximately 5 minutes before 10.00am BST on the day of results:  

https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918

 

A recording of the webcast will later be made available at ReNeuron's website, www.reneuron.com.

 

The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

 

For more information, please contact Buchanan on [email protected] or 020 7466 5000.

 

 

ENDS

 

 

ENQUIRIES:

 

ReNeuron

 +44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan (UK)

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham


 

Argot Partners (US)

Stephanie Marks, Claudia Styslinger

 

Stifel Nicolaus Europe Limited

     

  +1 212 600 1902

        

 

 +44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)


 

Nplus1 Singer Advisory LLP

 

+44 (0) 20 7496 3000

Aubrey Powell, Mark Taylor (Joint Broker)


 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCGGUWCQUPBGAM

Quick facts: ReNeuron Group PLC

Price: 126

Market: LSE
Market Cap: £40.11 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Punchy read-through valuation for ADM Energy's Nigerian oil...

Headlines from the Proactive UK newsroom. ADM Energy (LON:ADME) has had a punchy read-through valuation placed on its 5% stake in its field, offshore Nigeria. Petronor has acquired a 12.2% economic interest for US$10mln with a further US$25mln based on future gas production. Reneuron...

on 23/10/19